Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to $170.3 million.

  • Heron Therapeutics' Shares Outstanding (Weighted Average) rose 1146.24% to $170.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.3 million, marking a year-over-year increase of 1146.24%. This contributed to the annual value of $152.4 million for FY2024, which is 1036.23% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Shares Outstanding (Weighted Average) is $170.3 million, which was up 1146.24% from $152.4 million recorded in Q4 2024.
  • Over the past 5 years, Heron Therapeutics' Shares Outstanding (Weighted Average) peaked at $170.3 million during Q3 2025, and registered a low of $98471.0 during Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $119.2 million (2023), whereas its average is $118.7 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first crashed by 9989.15% in 2021, then soared by 11046656.27% in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' Shares Outstanding (Weighted Average) stood at $98471.0 in 2021, then surged by 110466.56% to $108.9 million in 2022, then grew by 26.87% to $138.1 million in 2023, then grew by 10.36% to $152.4 million in 2024, then grew by 11.74% to $170.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $170.3 million for Q3 2025, versus $152.4 million for Q4 2024 and $152.8 million for Q3 2024.